• Profile
Close

Model advances rational design of more effective maternal vaccines for newborns

ScienceDaily Dec 17, 2024

Newborns, with their developing immune systems, face high risks of infection in the critical early months of life. While maternal vaccines can bolster infant immunity by delivering antibodies through the placenta, these vaccines and their administration schedule are not optimised, and they don't always provide uniform protection for the whole population. Researchers from the University of Virginia's Department of Biomedical Engineering have created an advanced computational model that includes the key factors modulating antibody transfer from mother to fetus. In their recent review paper published in Nature Immunology, they describe how a mathematical modelling framework opens doors for safer, more effective maternal vaccines for vulnerable populations and has broad implications for newborn immunity.

Targeted maternal vaccines for newborns

Led by assistant professor of Biomedical Engineering Sepideh Dolatshahi and PhD student Remziye Wessel, the UVA team's research sheds light on the mechanisms driving selective antibody transfer across the placenta, particularly focusing on the IgG antibody that provides immunity to newborns. "Our model captures the kinetics and dynamic complexities of placental antibody transfer in ways that previous research simply couldn't," Dolatshahi said.

Dolatshahi also said that a mechanistic modelling approach paves the way for the rational design of maternal vaccines and personalised therapies by providing a framework for quantitatively assessing the relative impact of regulatory factors, as well as individual and population-level vulnerabilities, to more effectively protect all infants, including those born preterm, from serious infections.

This is a significant departure from traditional empirical vaccine design, which relied largely on static models or experimental model studies with limited applicability to human physiology. Instead, this model can integrate the dynamic changes in placental structure and maternal immune response over time, making it possible to identify kinetic bottlenecks that limit antibodies from reaching the fetus. By understanding these bottlenecks, researchers can develop maternal vaccines that are more effective at delivering the exact antibodies newborns need for immune defence.

 

Potential impact on newborns and broader patient populations

The implications of vaccine design from a modelling lens extend beyond newborns to other high-risk populations, including immunocompromised patients and elderly adults, who may benefit from similar models tailored to their unique needs.

For infants, the impact of optimised maternal vaccines could be life-saving, especially for those born prematurely, who often lack the full maternal antibody protection provided during a full-term pregnancy. Additionally, the model could enable the design of vaccines targeting specific infectious diseases that pose significant risks to newborns, potentially reducing neonatal mortality worldwide.

"Think of the placenta as a selective filter," Dolatshahi describes. "Our model helps reveal which antibodies can pass through effectively and when." Armed with this knowledge, the team's ultimate goal is to develop vaccines that optimise this natural transfer process, strengthening immunity for vulnerable newborns during their first critical months.

Beyond infancy, this modelling approach could eventually inform vaccine strategies for populations with varying immune capabilities, such as individuals with chronic diseases or those undergoing treatments that suppress the immune system. The framework may also offer insights into how antibody transfer efficiencies vary by patient characteristics, such as age, exposure to stressors, or genetic background, paving the way for a more personalised approach to immunisation.

"The computational model is currently a research tool, requiring further validation before direct clinical application," Wessel said. "With additional refinement and validation, it could potentially be tested in the clinic to guide patient-specific vaccine strategies in the near future."

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay